Table 1.
Open in new tab

Baseline patient characteristics.

All patients [n = 45]
Gender
 Male20 [44%]
 Female25 [56%]
Age, years, median [IQR]38 [28.0, 46.5]
BMI, kg/m2, mean ± SD [n = 29]27.9 ± 7.2
Race/ethnicity
 Non-Hispanic White35 [78%]
 Non-Hispanic Black2 [4%]
 Hispanic1 [2%]
 Asian1 [2%]
 Other6 [13%]
Smoking status
 Former5 [11%]
 Current2 [4%]
Crohn’s disease
 Small bowel only4 [9%]
 Colon only7 [16%]
 Small bowel and colon34 [76%]
 Perianal disease24 [53%]
 Stricturing complications31 [69%]
 Penetrating complications27 [60%]
Disease duration, years, median [IQR]15 [10, 21]
Duration on upadacitiniba, days, mean ± SD248.3 ± 153.0
Indication for upadacitinib
Crohn’s disease36 [80%]
Inflammatory arthritis8 [18%]
Pyoderma gangrenosum1 [2%]
All patients [n = 45]
Gender
 Male20 [44%]
 Female25 [56%]
Age, years, median [IQR]38 [28.0, 46.5]
BMI, kg/m2, mean ± SD [n = 29]27.9 ± 7.2
Race/ethnicity
 Non-Hispanic White35 [78%]
 Non-Hispanic Black2 [4%]
 Hispanic1 [2%]
 Asian1 [2%]
 Other6 [13%]
Smoking status
 Former5 [11%]
 Current2 [4%]
Crohn’s disease
 Small bowel only4 [9%]
 Colon only7 [16%]
 Small bowel and colon34 [76%]
 Perianal disease24 [53%]
 Stricturing complications31 [69%]
 Penetrating complications27 [60%]
Disease duration, years, median [IQR]15 [10, 21]
Duration on upadacitiniba, days, mean ± SD248.3 ± 153.0
Indication for upadacitinib
Crohn’s disease36 [80%]
Inflammatory arthritis8 [18%]
Pyoderma gangrenosum1 [2%]

aPatients were followed until upadacitinib was discontinued.

IQR, interquartile range; SD, standard deviation; BMI, body mass index.

Table 1.
Open in new tab

Baseline patient characteristics.

All patients [n = 45]
Gender
 Male20 [44%]
 Female25 [56%]
Age, years, median [IQR]38 [28.0, 46.5]
BMI, kg/m2, mean ± SD [n = 29]27.9 ± 7.2
Race/ethnicity
 Non-Hispanic White35 [78%]
 Non-Hispanic Black2 [4%]
 Hispanic1 [2%]
 Asian1 [2%]
 Other6 [13%]
Smoking status
 Former5 [11%]
 Current2 [4%]
Crohn’s disease
 Small bowel only4 [9%]
 Colon only7 [16%]
 Small bowel and colon34 [76%]
 Perianal disease24 [53%]
 Stricturing complications31 [69%]
 Penetrating complications27 [60%]
Disease duration, years, median [IQR]15 [10, 21]
Duration on upadacitiniba, days, mean ± SD248.3 ± 153.0
Indication for upadacitinib
Crohn’s disease36 [80%]
Inflammatory arthritis8 [18%]
Pyoderma gangrenosum1 [2%]
All patients [n = 45]
Gender
 Male20 [44%]
 Female25 [56%]
Age, years, median [IQR]38 [28.0, 46.5]
BMI, kg/m2, mean ± SD [n = 29]27.9 ± 7.2
Race/ethnicity
 Non-Hispanic White35 [78%]
 Non-Hispanic Black2 [4%]
 Hispanic1 [2%]
 Asian1 [2%]
 Other6 [13%]
Smoking status
 Former5 [11%]
 Current2 [4%]
Crohn’s disease
 Small bowel only4 [9%]
 Colon only7 [16%]
 Small bowel and colon34 [76%]
 Perianal disease24 [53%]
 Stricturing complications31 [69%]
 Penetrating complications27 [60%]
Disease duration, years, median [IQR]15 [10, 21]
Duration on upadacitiniba, days, mean ± SD248.3 ± 153.0
Indication for upadacitinib
Crohn’s disease36 [80%]
Inflammatory arthritis8 [18%]
Pyoderma gangrenosum1 [2%]

aPatients were followed until upadacitinib was discontinued.

IQR, interquartile range; SD, standard deviation; BMI, body mass index.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close